Zhimeng Biopharma Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 16

Zhimeng Biopharma General Information

Description

Manufacturer of novel small-molecule therapeutics designed to treat chronic hepatitis B (CHB), liver diseases, and central nervous system (CNS) disorders. The company's platform utilizes medicinal chemistry, HBV capsid assembly modulation, toll-like receptor agonist development, and clinical trial execution, providing hepatology specialists, neurology centers, clinical researchers, and patients with small molecule drug candidates, HBV capsid modulators, and immune-modulating therapeutics to facilitate functional cure strategies for hepatitis B and treatments for neurological conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Building 32, Lane 388, Shengrong Road
  • Pudong New Area
  • Shanghai, 201210
  • China
+86 021
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Building 32, Lane 388, Shengrong Road
  • Pudong New Area
  • Shanghai, 201210
  • China
+86 021

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zhimeng Biopharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private 11-Aug-2022 Completed Generating Revenue
5. Later Stage VC (Series B) 29-Oct-2021 Completed Generating Revenue
4. Secondary Transaction - Private 03-Dec-2020 Completed Generating Revenue
3. Later Stage VC (Series A) 06-Nov-2020 Completed Generating Revenue
2. Early Stage VC 11-Nov-2019 $14.2M $14.2M Completed Generating Revenue
1. Early Stage VC 05-Feb-2018 Completed Generating Revenue
To view Zhimeng Biopharma’s complete valuation and funding history, request access »

Zhimeng Biopharma Patents

Zhimeng Biopharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025237304-A1 Amide compound for treating and/or preventing hepatitis virus infections Pending 14-May-2024
AU-2025217690-A1 Crystal form of tetrahydroisoquinoline compound and use thereof Pending 08-Feb-2024
WO-2025167886-A1 Crystal form of tetrahydroisoquinoline compound and use thereof Pending 08-Feb-2024
EP-4512804-A1 Rho-associated protein kinase inhibitor and preparation and use thereof Pending 20-Apr-2022
EP-4512804-A4 Rho-associated protein kinase inhibitor and preparation and use thereof Pending 20-Apr-2022 C07D403/14
To view Zhimeng Biopharma’s complete patent history, request access »

Zhimeng Biopharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zhimeng Biopharma Investors (16)

Investor Name Investor Type Holding Investor Since Participating Rounds
Advantech Capital Partners PE/Buyout Minority
Co-Stone Capital PE/Buyout Minority
Dawu Venture Capital Venture Capital Minority
DYEE Capital Asset Manager Minority
Fellow Partners Venture Capital Minority
You’re viewing 5 of 16 investors. Get the full list »

Zhimeng Biopharma FAQs

  • When was Zhimeng Biopharma founded?

    Zhimeng Biopharma was founded in 2015.

  • Where is Zhimeng Biopharma headquartered?

    Zhimeng Biopharma is headquartered in Shanghai, China.

  • What is the size of Zhimeng Biopharma?

    Zhimeng Biopharma has 10 total employees.

  • What industry is Zhimeng Biopharma in?

    Zhimeng Biopharma’s primary industry is Drug Discovery.

  • Is Zhimeng Biopharma a private or public company?

    Zhimeng Biopharma is a Private company.

  • What is Zhimeng Biopharma’s current revenue?

    The current revenue for Zhimeng Biopharma is .

  • How much funding has Zhimeng Biopharma raised over time?

    Zhimeng Biopharma has raised $103M.

  • Who are Zhimeng Biopharma’s investors?

    Advantech Capital Partners, Co-Stone Capital, Dawu Venture Capital, DYEE Capital, and Fellow Partners are 5 of 16 investors who have invested in Zhimeng Biopharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process